0001743881-26-000019
SEC filingRevenue surged 66.8% to $194.5M driven by higher royalties from Beyonttra product sales in EU and Japan, yielding 94.9% gross margins, while operating losses held steady at -$106.0M due to late-stage R&D investments.
BridgeBio Pharma reported Q1 2026 revenue of $194.5 million, up 66.8% from $116.6 million in the prior year quarter. This growth stemmed primarily from higher royalty revenue earned on net product sales of Beyonttra in the European Union, following EC approval in February 2025, and in Japan after pricing approval in May 2025. These international launches expanded the product's market reach, driving the topline acceleration while maintaining a high-margin royalty model.
Gross profit rose 61.9% to $184.6 million, achieving a 94.9% gross margin. This near-flawless rate underscores the capital-light nature of royalty streams, where cost of revenues remains minimal relative to topline, even as volumes increased. The efficiency here provides a strong foundation, allowing reinvestment into core biotech priorities without margin erosion.
Net loss narrowed 1.8% to -$166.6 million from -$169.6 million, with diluted EPS improving to -$0.84 from -$0.88. This slight progress indicates some operating leverage emerging from revenue growth, despite non-cash and investment-driven pressures. Management notes the company expects continued operating and net losses for the next several years, given its development-stage focus.
Cash from operations burned -$197.3 million, stable with the prior period after accounting for $69 thousand in capital expenditures—reflecting measured infrastructure spend. This burn rate aligns with sustained R&D intensity and supports the need for strategic capital management. BridgeBio continues exploring partnerships, divestitures, or delays in certain programs to enhance efficiencies, reduce expenses through restructuring, and extend runway amid expected future losses impacting working capital.